Bristol-Myers Squibb (BMY) management last Friday called a meeting with Wall Street analysts in what one described as a “semi-urgent fashion” in hopes of convincing investors that its $74 billion bid for Celgene (CELG) really is a good deal. But even after the session, Tim Anderson of Wolfe Research signaled that the odds the transaction will close are “not as high as some are thinking.”

The move came a week after two funds opposed the proposal, arguing Bristol stockholders are being asked to accept too much risk, because the transaction is priced “well below” asset value, and “could be more difficult to achieve than depicted” by Bristol management. The funds, Wellington Management and Starboard Value, openly expressed concerns that were already building among some investors.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy